Clin2
NCT06951334Possibly a fitNot yet recruiting

Vildagliptin for early Parkinson's disease

Parkinson's Disease

Treatments studied

Part of Brain & nervous system, Hormones & metabolism clinical trials.

This trial tests whether vildagliptin, a diabetes drug, can slow the progression of early Parkinson's disease. It is for people who have been diagnosed within the past three years and are already taking stable Parkinson's medications.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
66 people
Ages
40 years to 75 years
Study type
Interventional

Who can take part

  • You are between 40 and 75 years old.
  • You have been diagnosed with Parkinson's disease within the last 3 years.
  • You have been on a stable dose of your Parkinson's medications for at least 1 month.
  • Your Parkinson's is not too advanced (you can walk without help and have only mild balance issues).
  • You do not have diabetes or have not taken certain diabetes drugs (like GLP-1 or DPP-4 inhibitors).
  • You have no significant memory or thinking problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07804381Not yet recruiting· Phase 2
Sitagliptin for early Parkinson's disease

This trial tests whether sitagliptin, a diabetes drug, can slow the progression of early Parkinson's disease. It aims to see if the medication can protect brain cells and reduce symptoms, potentially offering a new way to treat Parkinson's.

NCT07725562Recruiting· Phase 2/Phase 3
VG081821AC tablets for early to mid-stage Parkinson's disease

This trial tests a new oral medication, VG081821AC, in people with early to mid-stage Parkinson's disease. The goal is to see if it can improve movement symptoms and slow the progression of the condition, and it may offer a new treatment option for those not yet on levodopa.

Beijing
NCT07229651Recruiting· Phase 2/Phase 3
Metformin for Parkinson's disease

This trial tests if metformin, a diabetes drug, can help people with Parkinson's disease. It may improve symptoms or slow progression.

Tanta
NCT06976268Recruiting· Phase 2/Phase 3
Testing BHV-8000 for early Parkinson's disease

This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.

Birmingham, Alabama
NCT07157735Recruiting· Phase 2
Testing an anti-inflammatory drug for early Parkinson's disease

This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.

Cambridge
NCT06732180Recruiting· Phase 1
Testing a new drug (GT-02287) for Parkinson's disease

This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.

Darlinghurst, New South Wales

Hear when a new Parkinson's Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.